Human CellExp™ Biotinylated CD80/B7-1, Human Recombinant

Biomolecule/Target: N/A

Synonyms: T-lymphocyte activation antigen CD80; B7-1; Activation B7-1 antigen; BB1; CTLA-4 counter-receptor B7.1; B7

Alternates names: T-lymphocyte activation antigen CD80; B7-1; Activation B7-1 antigen; BB1; CTLA-4 counter-receptor B7.1; B7

Taglines: A critical regulator of T- and B-cell responses

Taglines: USA

Country of Animal Origin: USA

NCBI Gene ID #.: 941

NCBI Gene Symbol: N/A

Gene Source: Human

Accession #: P33681

Recombinant: True

Source: HEK 293 cells

Purity by SDS-PAGE #: > 95% by SDS-PAGE

Assay: N/A

Purity: N/A

Assay #2: N/A

Endotoxin Level: N/A

Activity (Specifications/test method): Biotinylated CD-80-Fc can bind to immobilized Human CD28, Fc Tag (Cat. No. 9237 coated at 1 µg/mL, 100 µL/well) with a linear range of 0.03 – 0.81 µg/mL

Biological activity: N/A

Results: N/A

Binding Capacity: N/A

Unit Definition: N/A

Molecular Weight: ~51 kDa (Human Fc Tag fused to C-terminus, biotinylated)

Concentration: N/A

Appearance: Lyophilized protein

Physical form description: Lyophilized powder

Reconstitution Instructions: N/A

Background Information: B-lymphocyte activation antigen B7-1 (referred to as B7) also known as Cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). B7-1 and B7-2, together with their receptors CD28 and CTLA­4, constitute one of the dominant co-stimulatory pathways that regulate T­ and B­cell responses. Although both CTLA­4 and CD28 can bind to the same ligands, CTLA­4 binds to B7­1 and B7­2 with a 20 ­ 100 fold higher affinity than CD28 and is involved in the down­regulation of the immune response. CD80 works in tandem with CD86 to prime T cells and plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. Additionally, the up-regulation of CD80 has been linked to various autoimmune diseases, including multiple sclerosis, systemic lupus erythematosus and sepsis. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

Amino acid sequence: Val 35 - Asn 242

Handling: Centrifuge the vial prior to opening.

Usage: For Research Use Only! Not to be used in humans